文献速递血栓与止血

血小板与单核细胞:预测免疫性血小板减少症患者对血小板生成素受体激动剂临床反应的有力组合?

Platelets and monocytes: A dynamic duo aiding in the prediction of the clinical response to thrombopoietin receptor agonists in immune thrombocytopenia?
PubMed 文献 · Br J Haematol · 2025-01-03

本文为针对Osuna-Gómez等研究的评论文章,该研究在38例免疫性血小板减少症(ITP)患者中分析艾曲泊帕治疗时血小板-白细胞复合物。艾曲泊帕治疗后血小板计数升高与血小板-白细胞复合物增加相关,单核细胞结合血小板的百分比更高且单核细胞IL-10产生增加与有利的临床反应相关。这些发现提示分析血小板-单核细胞复合物可能作为预测ITP患者对艾曲泊帕临床反应的指标,但需进一步验证。

要点

  • 艾曲泊帕治疗后血小板计数升高与血小板-白细胞复合物增加相关。
  • 单核细胞结合血小板百分比更高且单核细胞IL-10产生增加与有利临床反应相关。
  • 血小板-单核细胞复合物有潜力作为预测艾曲泊帕临床反应的指标,但需进一步验证。

核心结论

  • 艾曲泊帕治疗后血小板计数升高与血小板-白细胞复合物增加相关。
  • 单核细胞结合血小板的百分比更高且单核细胞IL-10产生增加与对艾曲泊帕治疗的有利临床反应相关。
  • 这些发现揭示了分析血小板-单核细胞复合物作为预测ITP患者对艾曲泊帕临床反应指标的潜力,但需进一步验证。

研究设计与样本

  • 本文为针对Osuna-Gómez等研究的评论文章,该研究在38例ITP患者中分析艾曲泊帕治疗时的血小板-白细胞复合物。

主要发现

  • 艾曲泊帕治疗后血小板计数升高与血小板-白细胞复合物增加相关。
  • 单核细胞结合血小板的百分比更高且单核细胞IL-10产生增加与对艾曲泊帕治疗的有利临床反应相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with immune thrombocytopenia (ITP) suffer from an autoimmune bleeding disorder with an isolated low number of platelets. Platelets and megakaryocytes are targeted by the immune system, due to a loss of immune tolerance, via the action of platelet-autoantibodies and/or cytotoxic T cells. ITP is a highly variable disorder regarding the underlying biological mechanisms, disease trajectories and treatment responses. Predictive indicators are therefore strongly warranted. To analyze the predictive response to the thrombopoietin receptor agonist eltrombopag, in this issue of the British Journal of Haematology, Osuna-Gomez and co-workers research platelet-leukocyte complexes in 38 ITP patients upon treatment with eltrombopag. Elevated platelet counts upon treatment with eltrombopag were associated with increased complexes of platelets bound to leucocytes. A higher percentage of monocytes bound to platelets, with an increased IL-10 production in monocytes, was found to be associated to a favorable clinical response to treatment with eltrombopag. Further validation is required but these findings reveal the potential of analyzing platelet-monocyte complexes as a predictive indicator for the clinical response to eltrombopag in patients with ITP. Commentary on: Osuna-Gómez et al. Interplay of leucocyte-platelet complexes and clinical response to eltrombopag in immune thrombocytopenia patients. Br J Haematol 2025; 206:1200-1212.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Kapur R. Platelets and monocytes: A dynamic duo aiding in the prediction of the clinical response to thrombopoietin receptor agonists in immune thrombocytopenia? Br J Haematol. 2025. PMID: 39749433. doi:10.1111/bjh.19991

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。